中国肿瘤生物治疗杂志2025，Vol.32Issue(4)：413-417,5.DOI:10.3872/j.issn.1007-385x.2025.04.010
DC-CIK细胞辅助西妥昔单抗联合CAPEOX化疗方案治疗晚期结直肠癌52例
DC-CIK cell as an adjuvant to cetuximab combined with CAPEOX chemotherapy regimen for the treatment of 52 cases of advanced colorectal cancer
摘要
Abstract
Objective:To evaluate the clinical efficacy and safety of DC-CIK cell immunotherapy as an adjuvant to cetuximab combined with CAPEOX(oxaliplatin+capecitabine)chemotherapy regimen in the treatment of advanced colorectal cancer(CRC)with all RAS gene wild-type and BRAF gene wild-type.Methods:A retrospective analysis was conducted on the clinical data of 52 cases of advanced CRC treated in the Oncology Department of in the General Hospital of the Eastern Theatre Command between December 2020 and October 2023,with 26 cases in the control group and the observation group respectively.The observation group received DC-CIK cell therapy in addition to chemotherapy given to the control group.The clinical efficacy and adverse reactions of patients were recorded,and the recent efficacy,quality of life score,incidence of chemotherapy adverse reactions,the changes in tumour markers,and immune indicators before and after treatment were analysed.Results:Compared with those in the control group,the disease control rate(DCR)and quality of life of advanced CRC patients in the observation group were significantly improved(both P<0.05).The incidence of diarrheal/constipation and tumour marker CA72-4 were significantly reduced(all P<0.05),and the NK cell count increased significantly(P<0.05).Conclusion:DC-CIK cell immunotherapy,when used as an adjuvant to cetuximab in combination with the CAPEOX chemotherapy regimen in patients with advanced CRC,is safe and feasible.It can significantly improve the DCR and bring significant clinical benefits to patients.关键词
结直肠癌/树突状细胞/细胞因子诱导的杀伤细胞/细胞免疫治疗辅助化疗Key words
colorectal cancer(CRC)/dendritic cell(DC)/cytokine-induced killer cell(CIK cell)/cell immunotherapy as an adjuvant to chemotherapy分类
临床医学引用本文复制引用
汪耔璇,江龙委,陈一天,贾绍昌..DC-CIK细胞辅助西妥昔单抗联合CAPEOX化疗方案治疗晚期结直肠癌52例[J].中国肿瘤生物治疗杂志,2025,32(4):413-417,5.基金项目
东部战区总医院院管课题(No.22JCYYYB1) （No.22JCYYYB1）
